Reversin 121

Reversin 121 is a small molecule compound described in scientific literature as a cell-permeable, selective inhibitor of the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp, also known as ABCB1 or MDR1). It has been used primarily in preclinical research to study and reverse multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein, thereby increasing intracellular concentrations of chemotherapeutic agents. There is no evidence that Reversin 121 has been developed for clinical use or approved for any therapeutic indication. Its primary application remains experimental, serving as a tool compound to investigate mechanisms of drug resistance and potential strategies to overcome it.